S&P 500: 681.75 +0.1% NASDAQ 100: 601.92 +0.2% Dow Jones: 495.28 +0.1%

Cliff Asness’s ZBIO Holdings & Trades

First Buy
Q2 2025
Duration Held
2 Quarters
Largest Add
Q2 2025
+24,668 Shares
Current Position
24,584 Shares
$545,765 Value

Cliff Asness's ZBIO Position Overview

Cliff Asness (via Aqr Capital Management LLC) currently holds 24,584 shares of Zenas BioPharma, Inc. (ZBIO) worth $545,765, representing 0.00% of the portfolio. First purchased in 2025-Q2, this recently established position has been held for 2 quarters.

Based on recent 13F filings, Cliff Asness has initiated a new position in ZBIO, representing a fresh investment thesis on this company. Largest reduction occurred in Q3 2025, reducing 84 shares.

Analysis based on 13F filings available since 2013 Q2

Cliff Asness's Zenas BioPharma (ZBIO) Holding Value Over Time

Track share changes against reported price movement

Quarterly Zenas BioPharma (ZBIO) Trades by Cliff Asness

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2025 +24,668 New Buy 24,668 $9.69
Q3 2025 -84 Reduce 0.34% 24,584 $22.20

Cliff Asness's Zenas BioPharma Investment FAQs

Cliff Asness first purchased Zenas BioPharma, Inc. (ZBIO) in Q2 2025, acquiring 24,668 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Cliff Asness has held Zenas BioPharma, Inc. (ZBIO) for 2 quarters since Q2 2025.

Cliff Asness's largest addition to Zenas BioPharma, Inc. (ZBIO) was in Q2 2025, adding 24,668 shares worth $239,033.

According to the latest 13F filing for Q3 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 24,584 shares of Zenas BioPharma, Inc. (ZBIO), valued at approximately $545,765.

As of the Q3 2025 filing, Zenas BioPharma, Inc. (ZBIO) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.

Cliff Asness's peak holding in Zenas BioPharma, Inc. (ZBIO) was 24,668 shares, as reported at the end of Q2 2025.